// Jing-Zhi Guan 1,* , Cheng Cheng 2,* , Jian-Xin Wang 3,* , Jian-Yuan Chai 4 , Shi-Ping Gao 5 , Cong-Hong Shi 6 , Batunasong 7 , Lin Zhang 8 and Shao-Fei Yuan 9 1 Pharmaceutical Department, Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, China 2 Inner-Mongolia Branch, China Mobile Online Service Co, Limited, Hohhot Inner Mongolia, Hohhot, Inner Mongolia, China 3 Human Anatomy and Tissue Embryology, Weifang Medical University, NO.7166 Baotong Street, Weicheng District, Weifang, Shandong, China 4 Department of Gastroenterology, The Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China 5 General Surgery, The Fourth Hospital of Baotou in Inner Mongolia Autonomous Region, Qingshan District, Baotou, Inner Mongolia, China 6 Department of Cardiology, The Fourth Hospital of Baotou in Inner Mongolia Autonomous Region, Qingshan District, Baotou, Inner Mongolia, China 7 Anorectal, Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, China 8 Operation Room, Baotou Cancer Hospital, Qingshan District, Baotou, Inner Mongolia, China 9 Pharmaceutical Department, The Second Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China * These authors Jing-Zhi Guan, Cheng Cheng and Jian-Xin Wang contributed equally to this work as first authors Correspondence to: Shao-Fei Yuan, email: yuanshaofei1984@163.com Keywords : somatostatin; basic therapy; early postoperative inflammatory small bowel obstruction; meta-analysis Received: August 16, 2017 Accepted: October 29, 2017 Epub: December 23, 2017 Abstract Background and Aims: As a complications after abdominal operations, early postoperative inflammatory small bowel obstruction (EPISBO) is a problem for many patients. The use of somatostatin combined with basic therapy for treating this disease has been widely reported, but its efficacy and safety were have beenare controversial. Therefore, the present study carried out a systematic review of the clinical efficacy and safety of somatostatin combined with basic therapy for treating EPISBO. Methods: We performed computer retrieval from foreign databases (including PubMed, The Cochrane Library and Embase) and Chinese databases (including Sino Med, CNKI, VIP and WanFang Data), a supplementary search for literature to include, and manual retrieval of abstracts, books and non-electronic magazines related to the present research to ensure a high recovery rate. From all published relevant experimental studies in Chinese and English from the date of databases creation through December 10, 2016, randomized controlled trials on the curative efficacy of somatostatin combined with basic therapy for EPISBO were collected. The evaluation measures included the total effectiveness rate among patients, peristaltic sound recovery time, time of disappearance of abdominal pain, time until first defecation after operation, drainage of gastrointestinal decompression and length of stay after treatment. The studies were selected by two investigators independently to extract data according to the inclusion and exclusion criteria. The, Bias Risk Assessment Tool recommended of the Cochrane Review Hand book 5.2 was used to assess literature quality, and a meta-analysis was carried out by using Stata 12.0 software. Results: Thirty papers involving 2,257 cases were included. The meta-analysis indicated that for the treatment of EPISBO, somatostatin combined with basic therapy compared with basic treatment alone promotes peristaltic sound recovery [SMD=-1.10, 95% CI (-1.50, -0.69), P =0.001<0.01] and a higher total efficiency rate [RR=1.38, 95% CI (1.27, 1.48), P <0.00001]; and reduces the duration of abdominal pain [SMD=-1.55, 95% CI (-2.01, -1.09), P <0.00001] and time until first defecation after operation [SMD=-1.66, 95% CI (-2.71, -0.60), P <0.00001]. Early use of somatostatin reduces drainage from gastrointestinal decompression [SMD=-6.23, 95% CI (-7.64, -4.82), P <0.00001] and the length of stay [ n =9, SMD=-1.59, 95% CI (-2.11, -1.07), P <0.00001]. Conclusion: The current evidence shows that for EPISBO patients in China, somatostatin combined with basic therapy could clearly shorten the duration of abdominal pain, time until defecation recovery, length of stay and peristaltic sound recovery as well as significantly reduce gastrointestinal decompression., However, the present results indicate that there is no difference between the 2 methods in regard to improving the total effectiveness rate. Therefore, the conclusions of the present research proves that somatostatin combined with basic therapy can be used as an effective drug for treating EPISBO in the clinic, but high-quality RCT research is still needed in the future to validate these findings.
Read full abstract